MapLight Therapeutics, Inc. (MPLT) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders held by MapLight Therapeutics, Inc. on June 23, 2026. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market under the symbol MPLT.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Of the 42,610,079 shares outstanding as of the record date, 36,883,750 shares (approximately 86.56%) were present or represented by proxy. The following proposals were approved:
- Proposal 1: Election of Directors. Three nominees were elected to serve until the 2029 annual meeting.
- Martin Babler: 31,424,194 votes For; 3,575,737 votes Withheld.
- Troy Cox: 34,979,012 votes For; 20,919 votes Withheld.
- George Pavlov: 34,220,342 votes For; 779,589 votes Withheld.
- Broker Non-Votes: 1,883,819.
- Proposal 2: Ratification of Auditors. Stockholders ratified the selection of RSM US LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Votes For: 36,859,217
- Votes Against: 22,332
- Abstained: 2,201
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.
Key Facts for Investor Verification
- Verify the total number of shares outstanding (42,610,079) and the participation rate (86.56%) to assess shareholder engagement.
- Review the definitive proxy statement filed on April 29, 2026, for detailed biographies of the elected directors and the rationale for the auditor selection.
- Note the significant number of votes withheld for director Martin Babler (3,575,737) compared to the other nominees, which may warrant further investigation into shareholder sentiment.
- Confirm the fiscal year-end date of December 31, 2026, for future financial reporting expectations.